TWO · 6574.TWO
Mikobeaute International Co., Ltd.
NT$113.50-NT$2.00 (-1.73%)
Mikobeaute International Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 26.3% below the high.
Loading market information…
TWO · 6929.TWO · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
We Can Medicines Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 41.92% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
We Can Medicines Co., Ltd.’s next earnings report is currently expected on Nov 6, 2026, with estimated earnings per share of NT$0.15. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow We Can Medicines Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
We Can Medicines Co., Ltd. is a Taiwan-based enterprise that manages a network of pharmacies across the island. These retail establishments offer a diverse array of health-related products, encompassing pharmaceuticals, nutritional supplements, mother-and-baby care items, and various medical devices. The company markets many of these goods under its own VITALPLUS and Sapporo brand names. Founded in 1987, the firm's corporate headquarters are situated in Taichung, Taiwan, and it operates as a subsidiary of Yousheng Medical Technology Co., Ltd.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:43 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2024 | Aug 14, 2024 | -NT$0.08-153.33% vs estimate | NT$823.88M-0.01% vs estimate |
|---|
| Q4 2023 | Mar 31, 2024 | NT$0.26 | NT$818.10M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$113.50-NT$2.00 (-1.73%)
Mikobeaute International Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 26.3% below the high.
NT$43.50+NT$0.70 (+1.64%)
Grand Hall Enterprise Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 7.45% below the high.
NT$15.10NT$0.00 (0.0%)
Kuangli Bio-Tech Holdings Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 52.81% below the high.
NT$41.10NT$0.00 (0.0%)
Far East Bio-Tec Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 12.55% below the high.
NT$20.75NT$0.00 (0.0%)
Sino Tactful Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 15.48% below the high.
NT$10.75-NT$0.20 (-1.83%)
Jia Jie Biomedical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.39% below the high.
NT$16.90-NT$0.25 (-1.46%)
DaBomb Protein Biotech Corp.’s quoted price sits in the lower half of its reported 52-week range, 19.91% below the high.
NT$26.00-NT$0.10 (-0.38%)
Mao Bao Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.16% below the high.
